As the target of both cetuximab and AG1478 is EGFR, a receptor physically recognized and interacted by AREG, it remains unclear whether pharmaceutically targeting AREG with a target‐specific antibody is more effective in minimizing the acquired resistance of cancer cells. The gene discussed is AREG; the disease is cancer.